...

FDA grants full approval to Pfizer's COVID vaccine in major pandemic milestone




  • In Business
  • 2021-08-23 14:37:00Z
  • By NY Daily News

The U.S. Food and Drug Administration granted full approval Monday to the COVID-19 vaccine developed by Pfizer and BioNTech, whose shots are now the first to move beyond emergency status since the pandemic began.

The highly anticipated move is effective for people 16 and older. The vaccine will remain available under emergency use authorization for children 12-15 years old and for a third dose in individuals with certain underlying medical conditions, according to the FDA.

"The FDA's approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic," Acting FDA Commissioner Janet Woodcock said in a statement.

"While this and other vaccines have met the FDA's rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product," she said.

The full approval was expected to boost confidence in the vaccine, potentially encouraging some of the 85 million unvaccinated Americans to get the shots. Months after the federal government made COVID-19 vaccines widely available and free to all adults, about 40% of people 12 and older still have not been vaccinated, according to the U.S. Centers for Disease Control and Prevention.

"While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," Woodcock said. "Today's milestone puts us one step closer to altering the course of this pandemic in the U.S."

Monday's announcement also means Pfizer and BioNTech will be allowed to market their vaccine, which is not permitted under emergency status. The two companies plan to market the vaccine as Comirnaty, the FDA said.

Pfizer Chairman and CEO Albert Bourla celebrated the accomplishment on social media.

"Every day, I wake up proud of our team at @Pfizer. Proud of the work we do. Proud of the difference we are making. And I am especially proud today," Bourla tweeted.

"It is our hope that this news will instill even further public confidence in our vaccine and the science that made it possible," he said.

---

COMMENTS

More Related News

Experts divided over Covid booster shots days ahead of US rollout
Experts divided over Covid booster shots days ahead of US rollout

Health officials scramble to prepare for rollout despite a void of critical details amid chaos Needles preloaded with the Moderna and Pfizer Covid-19...

U.S. Booster Policy Is in Flux as Studies Add to Dissent
U.S. Booster Policy Is in Flux as Studies Add to Dissent

WASHINGTON - Almost a month ago, President Joe Biden announced a plan to make coronavirus booster shots available to most adults in the United States eight...

Pfizer Vaccine Still Effective, FDA Says Days Before Review Of Booster Proposal
Pfizer Vaccine Still Effective, FDA Says Days Before Review Of Booster Proposal

The Biden administration has planned to launch a booster shot campaign for the general public as early as next week.

FDA strikes neutral tone ahead of vaccine booster meeting
FDA strikes neutral tone ahead of vaccine booster meeting
  • World
  • 2021-09-15 18:05:32Z

Influential government advisers will debate Friday if there's enough proof that a booster dose of Pfizer's COVID-19 vaccine is safe and effective - the first...

White House Walks Political Tightrope With Plan To Criminalize Fentanyl
White House Walks Political Tightrope With Plan To Criminalize Fentanyl

President Joe Biden's administration hopes concessions to progressives can help win over Congress on confronting the opioid epidemic.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business